Levobest-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, contributing to decreased bronchoconstriction, inflammation, and mucus production. The synergistic action of these two agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Levobest-M is indicated for patients requiring both antihistaminic and leukotriene receptor antagonist therapy, particularly in cases where monotherapy is insufficient. It is generally well tolerated, with adverse effects such as headache, fatigue, and gastrointestinal discomfort being infrequent and mild. Caution is advised in patients with hepatic impairment, and the drug should be used under medical supervision in individuals with a history of neuropsychiatric events. Levobest-M offers an effective therapeutic option for improving quality of life in patients with allergic respiratory disorders by alleviating both immediate and delayed hypersensitivity reactions.